Introduction {#s1}
============

Ticks are found in the class of Arachnida, and they are classified into two families, hard ticks (*Ixodidae*) and soft ticks (*Argasidae*), each containing different genera and species of ticks ([@B1], [@B2]). Ticks are vectors of the causative agents of viral, bacterial and protozoan diseases in both animals and humans, and there has been an increasing incidence of several tick-borne pathogens (TBPs) in many parts of the world. After mosquitoes, ticks are considered to be the second most common vectors of pathogens to humans ([@B3]). They are competent vectors of disease-causing pathogens including *Borrelia burgdorferi sensu lato* (*s.l*.), *tick-borne encephalitis virus* (TBEV), and *Anaplasma phagocytophilum*. The most common tick-borne diseases and their vectors with different transmission cycles are presented in [Table 1](#T1){ref-type="table"} ([@B3]--[@B7]). As ticks can transmit a variety of pathogens, an alternative control approach is to target the tick vector itself, either interfering with tick blood feeding or with pathogen transmission.

###### 

Common tick-borne diseases and their vectors with different transmission cycles.

  **Tick-borne pathogens (TBPs)**                                     **Main affected host**       **Tick-borne diseases (TBDs)**                      **Time required for pathogen transmission**   **Main tick species**                                                                             **Transovarial transmission**   **References**
  ------------------------------------------------------------------- ---------------------------- --------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------- ----------------
  *Ehrlichia ruminantium*                                             Farm animal                  Heartwater                                          48--96 h                                      *Amblyomma hebraeum, A. variegatum*                                                               No                              ([@B3])
  *Anaplasma platys*                                                  Companion animal             Canine cyclic thrombocytopenia                      16--72 h                                      *Rhipicephalus sanguineus*                                                                        No                              ([@B3], [@B4])
  *Anaplasma phagocytophilum*                                         Human and farm animal        Human granulocytic anaplasmosis, tick-borne fever   24--48 h                                      *Ixodes ricinus*                                                                                  No                              ([@B3], [@B4])
  *Rickettsia rickettsii*                                             Human                        Rocky Mountain spotted fever                        10 h                                          *Dermacentor variabilis, D. andersoni, Rhipicephalus sanguineus, Amblyomma americanum*            Yes                             ([@B3]--[@B7])
  *Anaplasma marginale*                                               Farm animal                  Bovine anaplasmosis                                 24--48 h                                      *Rhipicephalus microplus, Dermacentor andersoni*                                                  No                              ([@B3]--[@B7])
  *Borrelia burgdorferi* (*sensu lato*)                               Human and companion animal   Lyme disease                                        16--72 h                                      *Ixodes scapularis, I. pacificus*                                                                 No                              ([@B3]--[@B7])
  *Crimean-Congo hemorrhagic fever virus*                             Human and farm animal        Crimean-Congo hemorrhagic fever                     Immediate                                     *Hyalomma impeltatum*                                                                             Yes                             ([@B3]--[@B7])
  *Louping ill virus*                                                 Farm animal                  Louping ill                                         Immediate                                     *Ixodes ricinus*                                                                                  No                              ([@B3]--[@B7])
  *Tick-borne encephalitis virus*                                     Human                        Tick-borne encephalitis                             Immediate                                     *Ixodes ricinus, I. ovatus, I persulcatus*                                                        Yes                             ([@B6])
  *Theileria annulata*                                                Farm animal                  Tropical theileriosis                               48 h                                          *Hyalomma anatolicum anatolicum, Hyalomma anatolicum excavatum, Rhipicephalus appendiculatus*     No                              ([@B3])
  *Babesia divergens, B. microti*                                     Human                        Human babesiosis                                    48--72 h                                      *Ixodes persulcatus*                                                                              Yes/ No                         ([@B6])
  *Babesia canis, B. vogeli*                                          Companion animal             Canine babesiosis                                   48 h                                          *Rhipicephalus sanguineus sensu lato* (*s.l*.), *Dermacentor reticulatus, Haemaphysalis leachi*   Yes                             ([@B3]--[@B7])
  *Babesia divergens, B. jakimovi, B. bovis, B. bigemina, B. ovata*   Farm animal                  Bovine babesiosis                                   48--216 h                                     *Rhipicephalus microplus, R. annulatus, Ixodes ricinus*                                           No                              ([@B3]--[@B7])

Globally, 1.3 billion cattle populations in the world are at risk of TBPs with an annual economic cost estimated to be US\$22--30 billion in 1996 ([@B8]). This economic cost is going to be higher now in 2020 as it has been over 20 years. Currently, tick control depends mainly on the application of conventional chemicals or synthetic acaricides, resulting in acaricidal resistant tick populations in several developing countries and contamination of the environment and food products ([@B9]). Therefore, new approaches such as immunological control via vaccination are urgently required for effective control. Of which, vaccines seem to be a promising, safe, sustainable, cost-effective and environment-friendly solution. Only two ectoparasite vaccines were reported commercially in the early 1990s: The Australian TickGARD® (Hoechst Animal Health) and Latin American Gavac® (Heber Biotec). Both vaccines are derived from *Rhipicephalus microplus* midgut membrane-bound recombinant protein BM86 ([@B10], [@B11]). Despite the effectiveness of these commercial BM86-based vaccines for the control of cattle tick infestations, they show strain to strain variation in vaccine efficacy and are effective against *Rhipicephalus* tick species mainly ([@B12]). It has been nearly 30 years since the first anti-tick vaccines became commercially available. The identification of effective antigens remains to be the biggest hurdle in the development of further anti-tick vaccines. Thus, strategies to identify anti-tick vaccine antigen(s) should be based on expanding our knowledge of the biology of the ticks and its interaction with pathogens. This review will, therefore, focus on how the identification and functional characterization of selected tick proteins, with a particular focus on saliva, blood digestive and membrane-associated proteins, could help in the fight against tick-transmitted diseases and discuss the proteins suitability as anti-tick vaccine candidates.

Saliva-assisted Transmission Blocking Vaccine Candidates {#s2}
========================================================

Saliva-assisted transmission (SAT) is defined as "the indirect promotion of arthropod-borne pathogen transmission via the actions of arthropod saliva molecules on the mammalian host" ([@B13]). This characteristic has been reported for most hematophagous arthropods including ticks. In this section, we review work that focuses on tick saliva proteins (TSPs) which are critical to the success of ticks as vectors of TBPs, and thus might serve as targets in tick antigen-based vaccines to prevent TBP infections. Saliva-assisted transmission blocking anti-tick vaccine candidates are listed in [Table 2](#T2){ref-type="table"} ([@B14]--[@B21]).

###### 

Saliva-assisted transmission blocking anti-tick vaccine candidates.

  **Salivary molecule**   **Pathogen**                      **Tick species**                  **Target mechanism**                                        **Activity**                                                                               **References**
  ----------------------- --------------------------------- --------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------
  TSLPI                   *Borrelia burgdorferi*            *Ixodes scapularis, I. ricinus*   Tick salivary lectin pathway inhibitor                      Facilitates transmission from ticks to mice and from mice to ticks                         ([@B14])
  tHRF                    *B. burgdorferi*                  *I. scapularis*                   Tick histamine release factor (vasodilation)                Promotes late stage feeding and thereby facilitates tick to host transmission              ([@B15])
  Salp15                  *B. burgdorferi*                  *I. scapularis*                   Secreted salivary protein (acquired immune responses)       Facilitates transmission from ticks to mice                                                ([@B16])
  Salp25 D                *B. burgdorferi*                  *I. scapularis*                   Salivary protein, antioxidant (acquired immune responses)   Facilitates transmission from mice to ticks                                                ([@B17])
  Salp16                  *Anaplasma phagocytophilum*       *I. scapularis*                   Secreted salivary protein (acquired immune responses)       Facilitates transmission from ticks to mice                                                ([@B18])
  Subolesin (SUB)         *B. burgdorferi*                  *I. scapularis*                   A reduction in tick weight and/or oviposition               Tick protective antigen (innate immune response, reproduction, and development of ticks)   ([@B19], [@B20])
  Subolesin (SUB)         *Tick-borne encephalitis virus*   *I. scapularis*                   Nuclear factor kappa B (NF-kB)                              Tick protective antigen (innate immune response, reproduction, and development of ticks)   ([@B19], [@B20])
  64P                     *Tick-borne encephalitis virus*   *I. scapularis*                   Dual-action (exposed and concealed)                         Tick cement protein, secreted glycine-rich proteins                                        ([@B21])
  Sialo L2                *B. burgdorferi*                  *I. scapularis*                   Secreted salivary protein (acquired immune responses)       Increases level of skin infection following syringe inoculation                            ([@B54], [@B55])
  Sialo L2                *phagocytophilum*                 *I. scapularis*                   Secreted salivary protein (acquired immune responses)       Protection by inhibiting inflammasome formation in mice                                    ([@B54], [@B55])
  Salp20                  *Borrelia garinii*                *I. scapularis*                   Secreted salivary protein (acquired immune responses)       Protection by inhibiting the complement pathway                                            ([@B27])

Blocking attachment of a tick to the host is not only impairing blood feeding but also the transmission of tick-borne diseases (TBDs). The process of attachment starts with the intrusion of the tick\'s mouthparts into the host skin, followed by anchoring of the tick by a cement cone that mostly comprises secreted glycine-rich proteins. The molecular weight of 15-kDa tick cement protein, 64P, was first identified from the African brown ear tick *Rhipicephalus appendiculatus* that has been evaluated for its direct effect on TBEV transmission. Vaccination of mice with recombinant forms of 64P (64TRPs, expressed as truncated) significantly diminished TBEV transmission. In guinea pig, rabbit, mice and hamster models, these cement proteins act as a dual-action vaccine by targeting both "exposed" and "concealed" antigens, resulting in mortality of engorged ticks. Further, 64TPRs have been shown as a broad-spectrum vaccine candidate against adult and immature stages of several tick species, including *Ixodes ricinus* and *Rhipicephalus sanguineus* ([@B22]). The protective effect of anti-tick immunity against TBEV infection underpins the concept of transmission-blocking vaccines. Unlike 64TRP antigen, immunization with TickGARD did not provide protection against lethal infection with TBEV. Thus, 64TRPs antigens have the potential candidate for broad-spectrum transmission-blocking vaccines ([@B21]). Apart from 64TRPs, subolesin (SUB) is the second anti-tick vaccine candidate in the context of TBEV infection. It is an ortholog of vertebrate and tick akirins (AKR) that could be potentially considered as a universal vaccine against multiple blood-sucking arthropods including mosquitoes and ticks. Vaccination with recombinant subolesin protein showed a reduction of tick infestations and transmission of *B. burgdorferi, Anaplasma marginale, A. phagocytophilum*, and *Babesia bigemina* ([@B19], [@B20]). Havlíková et al. ([@B23]) found that SUB vaccines did not have any effect on TBEV infection and transmission. However, TBEV infection increases SUB mRNA transcript levels in tick tissues, thus supporting a role for this molecule in tick innate response to virus infection. Pilot studies have used *Babesia* and *Anaplasma* infection models to characterize SUB, TROSPA (identified in *Ixodes scapularis* as a receptor for *B. burgdorferi*) and SILK (a protein present in tick saliva) as potential antigens to control pathogen transmission in cattle. Rabbit polyclonal antibodies generated against SILK, TROSPA and SUB were added to infected or uninfected bovine blood to capillary feed *R. microplus* ticks. The results from capillary feeding showed a substantial effect on tick body weight, mortality, and oviposition rate, but infection levels were not changed in ticks treated with these antibodies ([@B24]). Because of the variations in infection levels from tick to tick, this experiment reported that artificial capillary blood feeding was not an ideal approach to characterize the efficacy of tick-pathogen interactions ([@B24]).

Salp15, a glycosylated salivary protein, was first identified from the black-legged tick *I. scapularis*. It is coded by 408 bases, and has a molecular weight of 14.7 kDa. The sequence analysis revealed weak similarities with two motifs of Inhibin A, a member of the TGF-ß super-family, and contained a signal peptide at N-terminal, suggesting that the protein may have immunosuppressive and secretory activity ([@B21]). It inhibits CD4^+^ coreceptor of mammalian T cells activation, dendritic cell-induced T cell activation through interaction with the C-type lectin and complement activity ([@B25]). Furthermore, the Salp15 protein binds to the outer membrane protein (OspC) of *B. burgdorferi* and protects the evasion of immune responses against spirochetes upon entry into the vertebrate host ([@B16]), facilitating long-lasting survival of the spirochetes, host infection and pathogen transmission. RNA interference-mediated (RNAi) silencing of Salp15 in infected *I. scapularis* significantly decreased the bacterial load in mice. RNAi studies provide the first direct evidence that Salp15 promotes TBPs transmission ([@B16]). Vaccination of mice with Salp15 showed substantial protection (60%) from *B. burgdorferi* infection ([@B26]), which provided further evidence. Following the discovery of Salp15-mediated transmission of *Borrelia* by *I. scapularis*, other salp15 homologs have been identified in *Ixodes persulcatus, Ixodes ricinus, Ixodes affinis*, and *Ixodes sinensis* ticks, they also bind *Borrelia garinii* and *Borrelia afzelii* OspC to facilitate spirochete transmission ([@B26]). Generally, high sequence similarity across various *Ixodes* species not only suggests an important role in blood feeding and tick--pathogen interactions but may also lead to the development of an anti-tick vaccine against TBDs.

Most salivary proteins are responsible for pathogen transmission from an infected tick to a host, but some saliva proteins are considered to aid in the acquisition of the pathogen by uninfected feeding ticks. One such protein is Salp25D, a 25-kDa tick salivary antioxidant protein expressed in both the salivary glands and midguts of *I. scapularis*. It has significant homology to glutathione peroxidase antioxidant that has been proven to play a critical role in protecting *Borrelia* from reactive oxygen produced by neutrophils and facilitating *Borrelia* acquisition by ticks ([@B21]). Knockdown of Salp25D significantly reduced acquisition of spirochetes by ticks engorging on *B. burgdorferi*-infected mice, but did not affect *Borrelia* transmission from infected nymphs to uninfected mice. Vaccination of mice with Salp25D also decreased the acquisition of *Borrelia* by ticks to three-fold in comparison to the control group ([@B17]). Hence, it seems that Salp25D facilitates the transmission of *Borrelia* from infected mice to uninfected ticks by protecting spirochetes from the toxic products of neutrophils activated by tick feeding ([@B27]).

Several other salivary proteins have been identified that play an important role in *A. phagocytophilum*-vector interactions. They include Salp16, alpha1-3-fucosyltransferase, P11 and an antifreeze glycoprotein (IAFGP) ([@B21]). Salp16, a 16-kDa protein, was identified in the salivary glands of *I. scapularis* and plays a role in *A. phagocytophilum*-vector interactions. Silencing of Salp16 induced significant (90%) reduction of *A. phagocytophilum* migration from gut to salivary glands through the haemolymph ([@B18]). Another study showed a significant increase in nuclear G-actin and phosphorylated actin upon *A. phagocytophilum* infection that subsequently influenced Salp16 gene expression ([@B28]). Two proteins, namely alpha 1-3-fucosyltransferase and IAFGP (*I. scapularis* tick antifreeze glycoprotein) were also found to be up-regulated upon the presence of *A. phagocytophilum* in ticks. RNAi-mediated knockdown of IAFGP and alpha 1-3-fucosyltransferase showed a significant reduction of *A. phagocytophilum* load in ticks when fed on infected mice ([@B21]). These results suggest the important role of these genes in tick-host interactions. P11, a secreted salivary protein, was up-regulated in *A. phagocytophilum*-infected ticks, which has been demonstrated in RNAi. The protein was shown to bind to *A. phagocytophilum* and facilitate the uptake of the pathogen by tick haemocytes, suggesting that haemocytes transport the pathogen from the midgut to the salivary glands ([@B29]).

Ticks have adopted a unique strategy to control the effects of host-derived histamine, and they secrete salivary molecules that neutralize the inflammatory effect of histamine ([@B30]). The tick histamine release factor (tHRF) was first characterized from *I. scapularis* using 2D fluorescence differential gel electrophoresis (DIGE). Real-time PCR analysis revealed that tHRF was expressed in both tick saliva and midgut and up-regulated in *Borrelia*-infected ticks. tHRF-silenced ticks or immunization of mice with recombinant tHRF significantly impaired the efficiency of tick feeding and spirochete transmission ([@B15]). As tHRF is critical for *I. scapularis* feeding irrespective of *B. burgdorferi* infection, and preferentially expressed between 48 and 72 h post-tick attachment (while *B. burgdorferi* s.s. transmission begins 36--48 h post-tick attachment), it appears that the effect on *Borrelia* transmission is due to the ability of tHRF to promote engorgement rather than to a specific interaction as with Salp15. Besides, increased vascular permeability effect of histamine may lead to the dissemination of *Borrelia* injected by the tick into the feeding site ([@B15]). Blocking tHRF might offer a viable strategy to develop vaccines that block tick feeding and therefore transmission of tick-borne pathogens. An *I. ricinus* ortholog of *I. scapularis* tHRF has been identified, but it had no effect on tick feeding upon vaccination. These results suggested that ticks have a multifaceted control mechanism for histamine and redundancy in the expression of histamine releasing factor proteins ([@B31]).

It has been shown that inhibition of the complement cascade at the tick bite site would not only be beneficial for the tick attachment but could also play a role in the survival and transmission of vector-borne pathogens in the mammalian host. Characterization of Salp15-assisted transmission of Lyme spirochetes demonstrates the importance of alternative and classical complement pathways in vertebrate host control of the spirochete. Unlike Salp 15, tick mannose-binding lectin inhibitor (TSLPI) does not bind to *B. burgdorferi* but instead interacts with the lectin-complement system, inhibiting complement cascade activation and reducing complement-mediated lysis of *Borrelia*. It is a glycosylated secretory salivary protein of 8 kD that was first identified from the salivary glands of *I. scapularis*. Expression of TSLPI mRNA levels is up-regulated in salivary glands 24 h after tick attachment compared to uninfected ticks, facilitating the survival of the spirochete and pathogen transmission. TSLPI-silenced ticks, or immunization of mice with anti-TSLPI antibodies, hampered *B. burgdorferi* transmission and acquisition by ticks ([@B14]). An ortholog from *I. ricinus* inhibits the lectin complement pathway and protects *B. garinii* and *B. burgdorferi* s.s. from complement-mediated killing *in vitro*, but TSLPI-assisted transmission of *B. burgdorferi* s.s. has not been identified. The saliva of *Ornithodoros* species inhibits both the alternative and classical pathways, while several *Ixodes* species (*Ixodes uriae* and *Ixodes hexagonus*) inhibit the alternative complement pathway, indicating that complement inhibitor in tick saliva is one of the important steps following tick attachment ([@B13]).

A recent study found that *Amblyomma americanum* ticks might utilize countervailing functions of pro- and anti-inflammatory proteins to regulate the evasion of host defenses. Both *in vitro* and *in vivo* data analyses demonstrated that the ticks first secreted pro-inflammatory proteins (insulin-like growth factor binding-related proteins: *Aam*IGFBP-rP6L, *Aam*IGFBP-rP6S, and *Aam*IGFBP-rP-1) that activated macrophage into the pro-host defense phenotype and then secreted anti-inflammatory proteins (serpins, AAS41, and AAS27) to deactivate the activated immune cells including macrophages ([@B32]). Thus, the discovery of tick saliva immuno-modulatory proteins is highly sought after as these might serve as targets in tick-antigen based vaccines to prevent TBPs.

From Tick Biology To Anti-tick Vaccines {#s3}
=======================================

The tick biological processes are associated with host attachment, followed by feeding on the host, pathogen transmission to the host, intracellular blood digestion, nutrient extraction from the meal, as well as oviposition and egg-laying. Up to date, these approaches have offered several potential vulnerable targets for developing anti-tick vaccines ([Figure 1](#F1){ref-type="fig"}). Successful vaccination against the tick has been previously achieved by targeting tick gut antigen, such as Bm86. In this section, we review work that has focused on saliva, transmembrane, and blood digestive proteins that are targeted to date and link the research findings to our current understanding and approaches for the development of anti-tick vaccines.

![A schematic representation of tick physiological processes and involved molecules tested as vaccine candidates \[modified from ([@B78], [@B103])\]. The most promising vaccine candidates are underlined. The red arrow represents blood meal uptake, and the blue arrow represents saliva injection. Several tick protease inhibitor families have been reported in the salivary glands and implicated in both tick biology/physiology. Major blood digestive enzymes (cathepsin B, C, D, L, and Legumain), blood digestion, heme/iron metabolism, detoxification, and inter-tissue transport that may serve as rational targets for "anti-tick" intervention. SG, salivary glands; MG, midgut; OV, ovary; HLS2, *Haemaphysalis longicornis* serpin-2; RAS-1,2,3,4, *Rhipicephalus appendiculatus*; IRIS, *Ixodes ricinus* immunosuppressor; Sialostatin L, *Ixodes scapularis*; OmC2, *Ornithodoros moubata*; Metis-1, metalloproteases from *Ixodes ricinus*; BrRm-MP4, metalloproteases *Rhipicephalus* (*Boophilus*) *microplus*; HLMP1, *Haemaphysalis longicornis* metalloprotease.](fvets-07-00319-g0001){#F1}

Tick Salivary Protein Families With Anti-tick Vaccine Potential
---------------------------------------------------------------

Our knowledge of tick salivary glands and saliva components has substantially increased in recent years because of high-throughput transcriptomic, proteomic, and functional analysis ([@B33]). Hundreds or thousands of salivary proteins have been identified that are capable of modulating vertebrate host defense by impairing inflammatory reaction, hemostasis, complement cascade, and immunity. Some have been functionally annotated and can be grouped into several protein families, such as lipocalins, glycine-rich proteins, metalloproteases, anticoagulants of the madanin family, and mucins.

Metalloproteases
----------------

Tick metalloprotease proteins were identified in saliva, midgut and ovary and play a role in tick physiology, such as innate immunity, blood uptake, blood meal digestion, and vitellogenesis ([@B34]). Tick metalloproteases sequences from diverse tick species have been characterized, e.g., *I. scapularis, I. ricinus, Ornithodoros savignyi, R. sanguineus, R. microplus, A. americanum*, and *Amblyomma maculatum* ([@B35]). Putative metalloproteases (Metis 1 and Metis 2) were identified from the hard tick *I. ricinus*. RNAi-mediated gene silencing of Metis 1--2 induced a high mortality rate. Vaccination of rabbits with recombinant Metis 1 protein reduced both weight gain and oviposition rate of *I*. *ricinus*, but had no effect on mortality and feeding time of ticks ([@B36]). Immunization with another recombinant metalloprotease HLMP1 from the *Haemaphysalis longicornis* resulted in increased mortality up to 15% of ticks ([@B37]). The vaccine efficacy with recombinant metalloprotease BrRm-MP4 from the salivary glands of *R*. *microplus* was 60% ([@B38]). Due to these promising results, the therapeutic potential for metalloprotease proteins might be a challenging task due to their stability and the long-term maintenance of their activity ([@B33]).

Protease Inhibitor Families
---------------------------

Several tick protease inhibitor families have been reported in the salivary glands, which have an important role in tick--host interactions ([@B39]). There are four groups under serine protease inhibitors, namely Kunitz, trypsin inhibitor-like domain, Kazal-domain inhibitors, and serpins, while the cysteine protease inhibitors belong to the cystatin family ([@B40]). The therapeutic potential of Kunitz-, Kazal-type, and TIL-domain inhibitors are reviewed elsewhere ([@B40]). Here, we discuss the vaccine potential of the other two groups, serine protease inhibitors and cystatins.

Serine proteinase inhibitors (SERPINs) are one of the largest and most abundant super family of proteinase inhibitors that play essential roles in every living system, from animals to plants. This enzyme family is conserved throughout evolution, and these proteins are involved in normal tick physiology, including the production of antimicrobial peptides, melanization, innate immunity, and blood digestion ([@B41], [@B42]). A flexible reactive center loop (RCL) of SERPINs with a conserved domain structure of 350--400 amino acid residues makes their characteristic structure ([@B42]). It has been shown that SERPINs differ from Kunitz-domain protease inhibitors by a distinctive conformational change of the RCL during the inhibition of their target proteases ([@B43]). SERPINs also have the ability to bind various protease and non-protease ligands, for example kallistatin, nexin-1, headpin, maspin, C1-inhibitor, and antichymotrypsin ([@B44]). SERPINs sequences from diverse tick species have been identified, including *Amblyomma hebraeum, Amblyomma variegatum, A. americanum, A. maculatum, Dermacentor variabilis, H. longicornis, R. appendiculatus, R. microplus, I. ricinus*, and *I. scapularis* ([@B45]). Despite high numbers of SERPINs from different tick species being identified in both *in vitro* and *in vivo* experimental analyses, only a few of them have been characterized functionally. IRIS (*I. ricinus* immunosuppressor), an immunomodulatory serpin from the salivary glands of *I. ricinus*, has an effect on host defense mechanisms by interfering with the production of pro-inflammatory cytokines ([@B46]). IRIS, together with a serpin from *H. longicornis* (HLS1) and several other proteins, have methionine and cysteine in their reactive center loop (RCL) and lack a signaling peptide, suggesting intracellular rather than extracellular function. Immunization of rabbits with recombinant IRIS showed significant protection (up to 30% mortality of feeding nymphs and adults) against *I. ricinus* infestation, but had no effect on nymphs fed on vaccinated mice ([@B47]). HLS2 was identified from *H. longicornis*, and contains a signal sequence and RCL with high sequence similarities to both invertebrate and vertebrate serpins. HLS2 also demonstrated significant protective immunity against adults and nymphs fed on immunized rabbits ([@B48]). Four serpins (RAS-1,2,3,4) were identified from *R. appendiculatus* ([@B40]). They were tested in a vaccine trial either as a mix of recombinant RAS-1 and RAS-2 or as a cocktail composed of three antigens, RAS-3, RAS-4, and a 36-kDa immunodominant cement protein RIM36. Vaccination of cattle with recombinant RAS-1 and RAS-2 cocktail reduced the number of engorged *R. appendiculatus* nymphs by 61 and a 43% and 28 increase in mortality rate in adult males and females, respectively. Similarly, a combination of RAS-3, RAS-4, and RIM36 resulted in a 40% mortality rate for *R. appendiculatus* ticks and almost 50% for *Theileria parva*-infected female ticks. Nevertheless, no significant protective effect against infection with *T. parva* was reported ([@B49], [@B50]).

The second-largest group of tick protease inhibitors is cystatins that are ubiquitously distributed in a wide variety of organisms. Tick cystatins either modulate vertebrate biological processes during tick feedings, such as immunity, antigen processing and presentation, phagocytosis, cytokine expression, and apoptosis, or can regulate hemoglobin digestion in ticks, which is driven by cathepsins ([@B39]). There are four cystatin subgroups based on conserved sequence motifs and cystatin domains: type 1 cystatins (stefins), type 2 cystatins, type 3 cystatins (kininogens), and type 4 cystatins (histidine-rich proteins, fetuins) ([@B51]). Among them, type 1 and 2 cystatins have been reported in ticks. The type 1 cystatins are typically intracellular and non-secreted cysteine protease inhibitors, while type 2 cystatins are secreted proteins that contain signal peptides as well as single cystatin-like domain. The type 1 (stefins) was the first cystatin isolated from *R. (Boophilus) microplus* that can inhibit tick vitellin degrading cysteine endopeptidase (VDTCE) and human cathepsin L, suggesting an immunomodulatory role and interaction with the vertebrate pro-inflammatory immune system ([@B52]). Similarly to serpins, several cystatins from different tick species have been reported such as Bmcystatin from *R. microplu*s, one cystatin from *A. americanum*, type 2 cystatin from *H. longicornis*, type 1 intracellular cystatin from *H*. *longicornis*, JpIocys2 from *Ixodes ovatus*, Om-cystatin 1 and 2 from *Ornithodoros moubata* soft tick and sialostatin L, L2 from *I. scapularis* ([@B53]). Sialostatin L2 and sialostatin L, novel type 2 secreted cysteine protease inhibitors, were biochemically and immunologically characterized from the salivary glands of *I. scapularis* ticks that are potentially implicated in the transmission of TBPs. Sialo L2 has been found to interfere with interferon-mediated immune responses in mouse dendritic cells (DC), resulting in enhanced replication of TBEV in bone marrow DC. Further, Sialo L2 promotes infection of mice by impairing inflammasome formation upon the presence of *A. phagocytophilum* in macrophages through targeting caspase-1 mediated inflammation, suggesting an important role in tick--pathogen interactions ([@B54]). Moreover, RNA silencing of sialo L2 resulted in increased mortality of ticks (up to 40%), as well as reduced tick size. Similar effects were reported when *I. scapularis* nymphs were exposed to guinea pigs immunized with sialo L2 ([@B55]). Several other cystatins from different tick species have been reported. Cystatin OmC2 was identified from the soft tick *O. moubata*. Immunization of mice with recombinant OmC2 significantly reduced the feeding ability and increased mortality ([@B53]). The vast majority of cystatin protease inhibitors identified in saliva have anti-inflammatory and immunosuppressive effects at the tick-host interface, suggesting cystatins might also be attractive anti-tick vaccine candidates. Targeting cysteine protease inhibitors does not only block tick attachment to the host and acquisition of the blood meal, but also impairs tick-borne pathogen transmission as demonstrated by vaccination of guinea pig against sialostatin L2 from *I. scapularis* ([@B53], [@B55]).

Transmembrane Proteins {#s4}
======================

Vaccine efficacy of transmembrane proteins is well-established since Bm86-based vaccines in cattle tick *R*. *microplus* have shown to be an effective tick control strategy. It has been reported that global vaccine efficacies vary from 45 to 100% because of sequence heterogeneity in the Bm86 gene among geographically separated *R. microplus* strains. A study on Thai cattle ticks found that Bm86 sequences were 91--93% similar to the amino acid reference sequences ([@B56]). Nevertheless, it is still the best option available for controlling ticks. Studies with Bm95 (homolog of Bm86 from *R. microplus*) demonstrated that it protects against a wide range of cattle ticks from different localities, suggesting that the Bm95-based vaccine could be a more universal choice ([@B57], [@B58]). Similarly, vaccination with recombinant *Rhipicephalus annulatus* Ba86 (an ortholog of Bm86 from *R. microplus*) was protective against *R. annulatus* and *R. microplus* infestations. The vaccine efficacy of Ba86 was slightly higher for *R. annulatus* than for *R. microplus* as expected ([@B59]). A recombinant *Hyalomma anatolicum anatolicum* Haa86 antigen is a Bm86 ortholog that is not only effective against tick infestations but also decreased *Theileria annulata* transmission ([@B60], [@B61]). ATAQ, a new member of promising antigen has been identified from metastriate ticks with high sequence similarity with Bm86 which is expressed in the tick gut and Malpighi tubes, unlike Bm86 orthologs that are expressed primarily in tick midgut ([@B62]). This novel protein contains specific epidermal growth factor-like domains (EGF-like) that could be considered as multi-antigen vaccine combination with carriers and adjuvants ([@B63]). Apart from Bm86 orthologs and homologs, the only other published antigen with a membrane association was aquaporin. Tick aquaporins belong to the membrane intrinsic protein (MIP) superfamily which is known to play a key role in the transportation of water, glycerol, and urea across the cell membrane. Osmoregulation and water balance functions of aquaporins were examined in *I. ricinus* by RNAi, which significantly reduced the body weight of semi-engorged females that fed for 5 days. A reported 75% vaccination trial efficacy has been reported against *R. microplus* infestations ([@B64]). Transcriptome studies of *R. microplus* showed that RmAQP1 as a potential vaccine antigen has significant amino acid sequence similarity to the human aquaporin 7 family and bovine AQP1 orthologs ([@B64]). This challenge can potentially be overcome by identifying highly conserved peptide motifs among tick AQP1 that differ from bovine and human AQP1 ([@B65]). It should be further tested against different tick species in different geographical regions.

Transmembrane proteins (TM) prediction using bioinformatic methods are reliable because of their transmembrane topology, simple structural features, signal peptide, and membrane-spanning regions ([@B66]). Richards et al. ([@B67]) have identified 878 putative TM from *R. microplus* which contribute to our understanding of membrane proteins as a whole and the possibility of using the identified proteins as anti-tick vaccines. TM (as a protein family) have not yet been fully exploited in vaccination studies, though their conserved molecular functions in both prokaryotic and eukaryotic organisms, such as chemical communication between the cell and its environment, cell-cell interactions, metabolism, transport of metabolites through ion channels, signal transduction, and recognition ([@B68]). More than 50% of the marketed drugs are targeting peptidergic G-protein-coupled receptors (GPCRs), highlighting their potential pharmacological and biological roles. GPCRs, also called seven-transmembrane receptors, are the most intensively studied drug targets in human medicine. Thus, the discovery of a tick neuropeptide GPCR may have commercial potential for tick control as lead molecules for drug/vaccine development. Moreover, there are no true orthologous mammalian receptors of the tick kinin receptor, which makes it an attractive potential ([@B69], [@B70]).

Blood Digestion Machinery in Ticks {#s5}
==================================

The digestive tract in both ecto- and endoparasites is an excellent potential target for vaccine development, especially through the inhibition of blood digestion ([@B71]). It has been reasonably well-established that the tick digestive system is divided into three compartments, namely the foregut, midgut, and hindgut, and each part is further subdivided based on their function and location ([@B72]). Digestive cells of the tick midgut are playing an important role in blood digestion. Feeding and digestion of host blood are fundamental biological processes for ticks, which are essential for nutrition, development and transmission of pathogens. Unlike blood-feeding insects that digest blood in the neutral or alkaline pH of the gut lumen ([@B73]), ticks digest hemoglobin and other proteins intracellularly (within the endosomes of gut epithelium) in the acidic lysosome-like vesicles of digestive cells lining the midgut epithelium ([@B74]). There are notable differences in blood-feeding strategies between soft and hard ticks. Hard tick blood feeding lasts for several days or even longer followed by rapid engorgement (10--22 h), and feed only once in each active life-cycle stage. In contrast to hard ticks, soft ticks take their blood meal very rapidly (0.5--1 h), and oviposition and feeding of their females are repeated. Following blood feeding, midgut epithelium uses receptor-mediated endocytosis and fluid-phase endocytosis (RME) to take up blood meals from the gut lumen ([@B75]). Tick hemoglobinolytic systems are carried out by an acidic peptidase (optimum pH 3.5) that contains aspartic peptidases of the cathepsin D type, cysteine endo, and exopeptidases of the papain type (cathepsin C, B, and L) and asparaginyl endopeptidases of the legumain type ([@B75]). This multi-enzyme cascade and unique mechanism of activation and substrate binding have the potential for vaccine or drug discovery, as demonstrated by the results of RNAi-mediated silencing of individual peptidases in non-insect arthropods ([@B75]). For example, knockdown of cathepsin B (longipain) in *H. longicornis* by RNAi resulted in reduced blood digestion and transmission of *Babesia* spp. to the host. Similarly, the silencing of legumain gene (HlLgm1 and HlLgm2) in *H. longicornis* resulted in reduced oviposition rate, as well as reduced engorged-tick body weight ([@B76]).

The proposed hemoglobinolytic pathway was uncovered in the hard tick *I. ricinus* using proteomic analysis \[([@B75]); [Figure 2](#F2){ref-type="fig"}\]. Three endopeptidases are most likely responsible for gradual degradation of the hemoglobin substrate, namely cathepsin D (clan AA aspartic peptidases), cathepsin L (clan CA cysteine peptidases), and legumain (clan CD cysteine peptidases). Among these, aspartic cathepsin D is the most dynamic enzyme with high turnover efficiency. Subsequently, the cysteine proteases, namely cathepsin B (clan CA papain-family peptidase) and cathepsin C (clan CA dipeptidyl-peptidase) are the most abundant intestinal peptidases in the next phases of the hemoglobinolysis that cleave large hemoglobin fragments into dipeptides ([@B75]). Lists of cysteine and aspartic peptidases identified from different tick species are presented in [Table 3](#T3){ref-type="table"}.

![A proposed model for the hemoglobinolytic pathway in *I. ricinus* \[modified from ([@B75])\]. The enzymes are color-coded according to clan membership- AA clan aspartic peptidases (red), CD clan cysteine peptidases (purple), CA clan (papain family) cysteine peptidases (green), and serine and metallopeptidases (black). The endopeptidases, cathepsin D (CatD) supported by cathepsin L (CatL) and legumain (AE), are responsible for the primary cleavage of hemoglobin. The production of secondary small fragments is dominated by the endopeptidase activity of cathepsin B (CatB). Exopeptidases act on the peptides released by the action of the endopeptidases through the carboxy-dipeptidase activity of CatB and the amino-dipeptidase activity of cathepsin C (CatC). Monopeptidases, including leucine aminopeptidase (LAP) and serine carboxypeptidase (SCP), might participate in the liberation of free amino acids.](fvets-07-00319-g0002){#F2}

###### 

Lists of cysteine and aspartic peptidases identified from different tick species \[modified from ([@B75])\].

  **Tick species**              **Type of peptidases**   **Name of peptidase**   **Functional characterization**          **Tissue expression**
  ----------------------------- ------------------------ ----------------------- ---------------------------------------- ----------------------------------------------------------
  *Haemaphysalis longicornis*   Serine proteases         HlSP, HlSP2, HlSP3      RNAi and recombinant enzymes             Midgut and midgut lumen
  *Haemaphysalis longicornis*   Legumain                 H1Lgm, H1Lgm2           RNAi and recombinant enzymes             Midgut
  *Ixodes ricinus*              Cathepsin L              IrCL1                   RNAi and native or recombinant enzymes   Midgut, salivary glands, ovaries, and Malpighian tubules
  *Rhipicephalus microplus*     Cathepsin L              BmCL1                   Native or recombinant enzymes            Midgut
  *Haemaphysalis longicornis*   Cathepsin B              Longipain               RNAi and recombinant enzymes             Midgut
  *Ixodes ricinus*              Cathepsin D              IrCD1                   RNAi and native or recombinant enzymes   Midgut
  *Haemaphysalis longicornis*   Cathepsin D              Longepsin               RNAi and recombinant enzymes             Midgut and salivary glands
  *Haemaphysalis longicornis*   Leucine amidopeptidase   HlLAP                   RNAi and recombinant enzymes             Midgut, salivary glands, ovaries, and epidermis
  *Ixodes ricinus*              Legumain                 IrAE                    RNAi and native or recombinant enzymes   Midgut
  *Haemaphysalis longicornis*   Cathepsin L              H1CPL-A                 Recombinant enzymes                      Midgut
  *Ixodes ricinus*              Cathepsin C              IrCC                    Native enzyme                            Midgut, salivary glands, ovaries, and Malpighian tubules
  *Ixodes ricinus*              Cathepsin B              IrCB1                   Native enzyme                            Midgut
  *Rhipicephalus microplus*     Cathepsin D              BmAP                    Native enzyme                            Midgut

A recent study showed that vaccination with cathepsin D has the potential to control poultry red mite infestations of chickens ([@B77]). However, vaccination trials on animals with an individual recombinant digestive enzyme, along with a cocktail of recombinant antigens, did not induce any significant level of protection against *I. ricinus* ([@B78]). Because of aspartic peptidases (APDs) redundancy in tick digestive apparatus, a multi-enzyme target strategy (a combination of aspartic and cysteine protease) might be necessary to exploit tick digestive hemoglobinolytic enzymes as new candidate antigens for the development of tick vaccines. It has been proposed that parasite vaccines should be based on at least two enzymes involved in different physiological processes, for example, blood digestive protein, together with proteins involved in essential physiological processes of ticks. As such, two combined recombinant hookworm antigens, glutathione S-transferases (GSTs) and cathepsin D-like aspartic protease haemoglobinase (APR-1), eventually became a leading vaccine candidate against the human hookworm *Necator americanus* ([@B79]). In this regard, a multi-antigenic vaccine against *R. microplus* was tested on cattle under field conditions. Vaccination studies with recombinant *Boophilus* yolk pro-cathepsin (BYC) and vitellogenin degrading cysteine endopeptidase (VTDCE) from *R*. *microplus*, and Hl-GST from *H. longicornis* affect tick physiology, decrease the number of semi-engorged female ticks in the host, resulting in an improved body weight gain of cattle ([@B80]). Similarly, cathepsin L and cathepsin D both have potential as vaccine antigens as part of a multi-component vaccine for controlling the poultry red mite *Dermanyssus gallinae* ([@B81]). Future work should be focused on identifying the appropriate synergistic combinations of these proteins to develop a cocktail vaccine for novel therapeutic interventions.

Iron Acquisition and Metabolism {#s6}
===============================

During blood feeding, ticks have to protect themselves from the toxicity of heme and iron from the host blood. Free iron radicals are potentially toxic for all organisms that cause substantial damage to lipids, DNA and protein molecules ([@B82]). Unlike ticks, iron originated from heme degradation in hematophagous insects is catalyzed by heme oxygenase (HO) ([@B83]). This trait is, however, absent from other blood feeding non-insect arthropods like ticks and mites. Ticks possess a complex biochemical process via hemosome formation that efficiently utilizes non-heme iron within the tick body. Three proteins are involved in vertebrate iron metabolism, namely ferritin (Fer) and the iron regulatory proteins (IRP1) and IRP2 ([@B84]). Intracellular ferritin (Fer1) was identified in both soft and hard ticks, which shared sequence similarity with mammalian heavy-chain ferritins and conserved ferroxidase sites ([@B85]). Afterward, Fer2 and iron-responsive protein (IRP) were described in *I*. *ricinus*, which are exclusively expressed in tick gut, and are required for iron transport to the peripheral tissues for their normal function ([@B84]). It has been shown that Fer2 possesses all the important characteristics for the development of a vaccine, including: not being presented in the vertebrate host (concealed antigen property), non-redundancy gene, low homology to mammalian ferritins, and host antibodies can directly contact the tick gut while feeding on a vaccinated host ([@B86]). A study showed that vaccination with recombinant tick Fer2 has the potential to control tick infestations on rabbits against *I. ricinus* ([@B87]) and *H. longicornis* ([@B88]). Essentially, the vaccine efficacy of recombinant Fer2 from *R. microplus* was comparable with the commercial vaccine based on the Bm86 antigen ([@B87]). Furthermore, GSTs are present in ticks where they serve primarily in biological detoxification. This enzyme is capable of binding heme in blood-feeding arthropods including ticks, suggesting that GSTs can serve as detoxifying molecules. A vaccination trial on bovines with recombinant GST from *H. longicornis* showed a cross-protection immunity against infestation with *R. microplus* ([@B89]).

Reverse Vaccinology Approaches in Antigen Discovery {#s7}
===================================================

According to Louis Pasteur\'s principle, vaccine development was based on the "isolate--inactivate--inject" approach before the 1990s. The "first generation" vaccine included live, attenuated and killed types, while the "second generation" vaccine consisted of purified or recombinant components of the targeted antigen. Nevertheless, this approach is a long and laborious task even in successful projects. Besides, these approaches are often unsuccessful because of the complexity of tick\'s life cycle, complicated host-pathogen-tick interactions and pathogens not possessing clear immunogenic properties. Thus, next-generation vaccination approaches might overcome these challenges by using a combination of functional genomics, bioinformatics and systems biology methodologies ([@B90]). This method involves *in silico* screening of the whole genome of a tick to identify genes with important immunogenic properties followed by wet lab verification with vaccination trials. Tick antigens developed based on biological processes and vaccine approaches tested for vaccine development against ticks are listed in [Table 4](#T4){ref-type="table"} ([@B91]--[@B95]).

###### 

Tick antigens developed based on biological process and vaccine approaches tested for vaccine development against ticks.

  **Protein type**      **Species**                                                                                        **Identity of protein**         **Antigen**           **Vaccination approach**              **Efficacy of vaccine**              **References**
  --------------------- -------------------------------------------------------------------------------------------------- ------------------------------- --------------------- ------------------------------------- ------------------------------------ --------------------------
  Secreted              *Rhipicephalus appendiculatus, R. sanguineus*                                                      Putative cement protein         64TRP                 Recombinant protein, 2nd generation   62 and 47% mortality                 ([@B21], [@B22])
                        *Rhipicephalus appendiculatus*                                                                     Serine protease inhibitor       RAS-3, RAS-4, RIM36   Recombinant protein, 2nd generation   39 and 48% mortality                 ([@B49], [@B50])
                        *Ixodes scapularis*                                                                                Cystatin type 2                 Sialostatin L2        Recombinant protein, 2nd generation   40% mortality                        ([@B55])
                        *Ixodes scapularis*                                                                                Cystatin type 2                 Sialostatin L         Recombinant protein, 2nd generation   Not reported                         ([@B55])
                        *Ixodes ricinus*                                                                                   Serine protease inhibitor       IRIS                  Recombinant protein, 2nd generation   30% mortality                        ([@B47])
                        *Rhipicephalus microplus, R. annulatus*                                                            Ferritin, iron transporter      RaFER2/RmFER2         Recombinant protein, 2nd generation   64 and 72% efficacy                  ([@B87])
  Membrane associated   *Rhipicephalus microplus*                                                                          Angiotensin converting enzyme   Bm91                  Recombinant protein, 2nd generation   6% reduction of reproductive index   ([@B91])
                        *Rhipicephalus microplus, R. annulatus*                                                            Aquaporin                       Aquaporin             Reverse vaccinology, 3rd generation   75 and 68% efficacy                  ([@B64], [@B65])
                        *Rhipicephalus appendiculatus, R. decoloratus, R. microplus, Hyalomma anatolicum, H. dromedarii*   Bm86 and orthologs              Bm86 and orthologs    Recombinant protein, 2nd generation   45--100% efficacy                    ([@B57]--[@B61])
                        *Rhipicephalus microplus*                                                                          5′-nucleotidase                 4F8                   Recombinant protein, 2nd generation   No efficacy                          ([@B92])
                        *Rhipicephalus microplus*                                                                          Mucin                           BMA7                  Purified components, 2nd generation   21% reduction in egg weights         ([@B93])
  Intracellular         *Rhipicephalus microplus*                                                                          Elongation factor               Ef1a                  Recombinant protein, 2nd generation   31% efficacy                         ([@B94])
                        *Rhipicephalus sanguineus, R. microplus*                                                           Acidic ribosomal protein P0     pP0                   Synthetic peptide, 2nd generation     96% efficacy                         ([@B95])
                        *Rhipicephalus microplus*                                                                          Glutathione S transferase       GST-HI                Recombinant protein, 2nd generation   57% efficacy                         ([@B89])
                        *Rhipicephalus annulatus, R. microplus*                                                            Regulator factor                Subolesin (4D8)       Recombinant protein, 2nd generation   0--83% efficacy                      ([@B19], [@B20], [@B23])
                        *Rhipicephalus microplus, R. annulatus*                                                            Ubiquitin                       UBE                   Recombinant protein, 2nd generation   15 and 55% efficacy                  ([@B94])

Reverse Vaccinology (RV) is a new methodology to design vaccines from systems biology and functional genomic information with the help of bioinformatics, which was first described in the year 2000 \[([@B96]); [Figure 3](#F3){ref-type="fig"}\]. Since approximately 2005, two types of RV approaches have been developed for the anti-tick vaccine study, one involving the use of gene knockdown study (RNAi) and the other involving the use of microarray analysis, EST library, subtraction libraries, and CattleTickBase approaches ([@B97]). RNAi has the potential to improve understanding of gene function where functional genomic data are limited. It has been reported in several tick species, namely *Rhipicephalus haemaphysaloides, A. americanum, H. longicornis, I. scapularis*, and *D. variabilis*. Another RV technique was developed based on a "systems biology" analysis of transcriptome datasets and RNAi screening of candidates, which identified aquaporin antigen from *R. microplus* ([@B64], [@B98]). Functional genomics has been applied to study the interaction of tick-pathogen-host for transmission blocking vaccine development. For example, molecular studies have been conducted to study the pathogen transmission at the tick-*Anaplasma* interface, either *in vitro* or *in vivo* ([@B99]). However, gene knockdown study is slow throughput, off-target effect, difficult to find an appropriate delivery system, the incompleteness of knockdowns and time-consuming approach ([@B100]). Hence, an alternative gene-manipulation approach such as CRISPR-based gene drive could be explored for the production of more efficient, stable, and safe parasite vaccines ([@B101], [@B102]).

![A schematic representation of the integrative reverse vaccinology approach toward vaccine development.](fvets-07-00319-g0003){#F3}

Conclusions {#s8}
===========

This review highlights the progress, opportunities, and challenges offered by recent research into vaccination, as well as provide a wealth of unprecedented information on the genes and proteins involved in the blood digestion process in the ticks, tick-host-pathogen interface, and proteins involved in pathogen transmissions, along with the discussion of potential vaccine targets in recent years. Based on our growing knowledge of tick genome complexity and protein superfamilies, tick vaccines are entering a new genomic era that will facilitate the discovery of novel vaccine antigens. It is becoming clear that the "One Health" approach is needed for developing anti-tick vaccines which means multidisciplinary sectors (biologists, immunologists, bioinformaticians, physicians, veterinarians and pharmaceutical industry, amongst others) communicate and work together to achieve better outcomes.
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